Epizyme Inc Drug Patent Portfolio
Epizyme Inc owns 1 orange book drug protected by 24 US patents Given below is the list of Epizyme Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10786511 | Method for treating cancer | 19 Dec, 2035 | Active |
| US10369155 | Method for treating cancer | 16 Oct, 2035 | Active |
| US9889138 | Method for treating cancer | 16 Oct, 2035 | Active |
| US9688665 | Methods of treating cancer | 22 Aug, 2034 | Active |
| US8410088 | Aryl- or heteroaryl-substituted benzene compounds | 23 Jan, 2034 | Active |
| US10245269 | Salt form of a human histone methyltransferase EZH2 inhibitor | 11 Apr, 2033 | Active |
| US10821113 | Salt form of a human histone methyltransferase EZH2 inhibitor | 11 Apr, 2033 | Active |
| US11491163 | Salt form of a human histone methyltransferase EZH2 inhibitor | 11 Apr, 2033 | Active |
| US9394283 | Salt form of a human histone methyltransferase EZH2 inhibitor | 11 Apr, 2033 | Active |
| US9872862 | Salt form of a human histone methyltransferase EZH2 inhibitor | 11 Apr, 2033 | Active |
| US11052093 | Aryl-or heteroaryl-substituted benzene compounds | 13 Apr, 2032 | Active |
| US9522152 | Aryl- or heteroaryl-substituted benzene compounds | 13 Apr, 2032 | Active |
| US10155002 | Aryl- or heteroaryl-substituted benzene compounds | 12 Sep, 2031 | Active |
| US10420775 | Aryl-or heteroaryl-substituted benzene compounds | 12 Sep, 2031 | Active |
| US8691507 | Inhibitors of human EZH2 and methods of use thereof | 12 Sep, 2031 | Active |
| US8765732 | Aryl- or heteroaryl-substituted benzene compounds | 12 Sep, 2031 | Active |
| US8895245 | Inhibitors of human EZH2 and methods of use thereof | 12 Sep, 2031 | Active |
| US9090562 | Aryl- or heteroaryl-substituted benzene compounds | 12 Sep, 2031 | Active |
| US9175331 | Inhibitors of human EZH2, and methods of use thereof | 12 Sep, 2031 | Active |
| US9333217 | Inhibitors of human EZH2, and methods of use thereof | 12 Sep, 2031 | Active |
| US9334527 | Inhibitors of human EZH2, and methods of use thereof | 12 Sep, 2031 | Active |
| US9549931 | Aryl- or heteroaryl-substituted benzene compounds | 12 Sep, 2031 | Active |
| US9855275 | Aryl-or heteroaryl-substituted benzene compounds | 12 Sep, 2031 | Active |
| US9949999 | Inhibitors of human EZH2, and methods of use thereof | 12 Sep, 2031 | Active |
Latest Legal Activities on Epizyme Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Epizyme Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549931 |
| Patent eCofC Notification | 11 Jun, 2024 | US9394283 |
| Mail Patent eCofC Notification | 11 Jun, 2024 | US9394283 |
|
Email Notification
Critical
| 11 Jun, 2024 | US9394283 |
| Recordation of Patent eCertificate of Correction | 11 Jun, 2024 | US9394283 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jun, 2024 | US9522152 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10821113 |
|
Email Notification
Critical
| 17 Apr, 2024 | US9889138 |
|
Email Notification
Critical
| 16 Apr, 2024 | US9889138 |
| Mail Patent eCofC Notification | 16 Apr, 2024 | US9889138 |
| Recordation of Patent eCertificate of Correction | 16 Apr, 2024 | US9889138 |
| Patent eCofC Notification | 16 Apr, 2024 | US9889138 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 11 Apr, 2024 | US8895245 |
|
Email Notification
Critical
| 11 Apr, 2024 | US8895245 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Apr, 2024 | US8410088 |
Epizyme Inc Drug Patents' Oppositions Filed in EPO
Epizyme Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 02, 2016, by Glaxosmithkline Intellectual Property (No.2) Limited. This opposition was filed on patent number EP11824247A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11824247A | Nov, 2016 | GlaxoSmithKline Intellectual Property (No.2) Limited | Granted and Under Opposition |
Epizyme Inc's Family Patents
Epizyme Inc drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 20.2% of its total global patent coverage. Click
below to unlock the full patent family tree.
Epizyme Inc Drug List
Given below is the complete list of Epizyme Inc's drugs and the patents protecting them.
1. Tazverik
Tazverik is protected by 24 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10786511 | Method for treating cancer |
19 Dec, 2035
(10 years from now)
| Active |
| US10369155 | Method for treating cancer |
16 Oct, 2035
(10 years from now)
| Active |
| US9889138 | Method for treating cancer |
16 Oct, 2035
(10 years from now)
| Active |
| US9688665 | Methods of treating cancer |
22 Aug, 2034
(9 years from now)
| Active |
| US8410088 | Aryl- or heteroaryl-substituted benzene compounds |
23 Jan, 2034
(9 years from now)
| Active |
| US10245269 | Salt form of a human histone methyltransferase EZH2 inhibitor |
11 Apr, 2033
(8 years from now)
| Active |
| US10821113 | Salt form of a human histone methyltransferase EZH2 inhibitor |
11 Apr, 2033
(8 years from now)
| Active |
| US11491163 | Salt form of a human histone methyltransferase EZH2 inhibitor |
11 Apr, 2033
(8 years from now)
| Active |
| US9394283 | Salt form of a human histone methyltransferase EZH2 inhibitor |
11 Apr, 2033
(8 years from now)
| Active |
| US9872862 | Salt form of a human histone methyltransferase EZH2 inhibitor |
11 Apr, 2033
(8 years from now)
| Active |
| US11052093 | Aryl-or heteroaryl-substituted benzene compounds |
13 Apr, 2032
(7 years from now)
| Active |
| US9522152 | Aryl- or heteroaryl-substituted benzene compounds |
13 Apr, 2032
(7 years from now)
| Active |
| US10155002 | Aryl- or heteroaryl-substituted benzene compounds |
12 Sep, 2031
(6 years from now)
| Active |
| US10420775 | Aryl-or heteroaryl-substituted benzene compounds |
12 Sep, 2031
(6 years from now)
| Active |
| US8691507 | Inhibitors of human EZH2 and methods of use thereof |
12 Sep, 2031
(6 years from now)
| Active |
| US8765732 | Aryl- or heteroaryl-substituted benzene compounds |
12 Sep, 2031
(6 years from now)
| Active |
| US8895245 | Inhibitors of human EZH2 and methods of use thereof |
12 Sep, 2031
(6 years from now)
| Active |
| US9090562 | Aryl- or heteroaryl-substituted benzene compounds |
12 Sep, 2031
(6 years from now)
| Active |
| US9175331 | Inhibitors of human EZH2, and methods of use thereof |
12 Sep, 2031
(6 years from now)
| Active |
| US9333217 | Inhibitors of human EZH2, and methods of use thereof |
12 Sep, 2031
(6 years from now)
| Active |
| US9334527 | Inhibitors of human EZH2, and methods of use thereof |
12 Sep, 2031
(6 years from now)
| Active |
| US9549931 | Aryl- or heteroaryl-substituted benzene compounds |
12 Sep, 2031
(6 years from now)
| Active |
| US9855275 | Aryl-or heteroaryl-substituted benzene compounds |
12 Sep, 2031
(6 years from now)
| Active |
| US9949999 | Inhibitors of human EZH2, and methods of use thereof |
12 Sep, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tazverik's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List